SBIR/STTR Research Award

Therapeutic Ultrasound Contrast Agent Dynamics Modeling SBIR Phase II

Award identifier 1422c4750df9a37ca83ff02143ec53abab3261ec07fe9d0e823d327012e05050Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$749,397

Program and phase

SBIR · Phase II

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
DYNAFLOW, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
X2KFLRCASMG7
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Target drug and gene delivery are rapidly emerging applications for ultrasound contrast agents since they reduce potential deleterious side effects to healthy tissue and minimize the overall dose needed. Development of new contrast agents requires a good understanding of the effect of the properties of the viscous material of the shell and of the acoustic field on the dynamics of the agent and on the mechanism of breakup of the shell. A novel numerical code, which enables modeling of non-spherical contrast agent's dynamics acoustic waves and nearby boundaries and tissues is proposed. This model, whose feasibility was demonstrated in Phase I, will allow us to accurately predict the necessary conditions for breakup. In Phase I we coupled a Boundary Element Method solver and a Navier-Stokes solver and demonstrated 3D modeling of viscous thick shelled contrast agent including in the presence of rigid walls, and identified the mechanisms for shell breakup due to non-spherical deformations. In the Phase II study, we will complete, improve and expand the capabilities of the model to simulate viscoelastic shell material properties and simulate multiple contrast agents' interactions with deformable boundaries such as blood cells, tissues, and blood vessels. We will also validate the developed model experimentally using both a scaled-up test for visualization and actual contrast agents for breakup limit confirmation. PUBLIC HEALTH RELEVANCE: Success of this research will help pharmaceutical companies develop safer and more efficient drug and gene delivery agents. These agents are especially attractive to chemotherapy treatment because they can greatly reduce deleterious side effects to healthy tissue caused by many chemotherapy drugs and minimize the overall dose needed.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

73 SBIR/STTR records share this UEI (1990–2024). Reported award amounts total $16,579,394. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Defense, Department of Energy, Department of Health and Human Services, National Science Foundation, Department of Commerce, National Aeronautics and Space Administration

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.